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Congenital deficiencies of Transcobalamin II (TC II) and R binders of vitamin B12 (B,2,
cobalamin, Cbl) have been described in several families. The deficiency of TC II exists as at
least three variants. The deficiency ofTC II is expressed by a profound megaloblastic pancyto-
penia during the first few weeks oflife, but the serum Cbl is normal. In contrast, thedeficiency
of R binder is asymptomatic, tissues are replete in Cbl, but the serum Cbl is low. All of the R
binder in the several body sources is under the same genetic control. Studies of the congenital
deficiency ofTC II suggest the following: (1) The function ofTC II is the promotion ofcell up-
take ofphysiologic amounts ofCbl, which can also be accomplished by very large amounts of
Cbl, and not in any intracellular process. (2) TC II is essential for the absorption, postabsorp-
tive distribution, and recycling of TC II. (3) The metabolic consequences of TC II deficiency
are expressed primarily in rapidly dividing cells probably because they are dependent upon the
constant need for new Cbl.
The intent of this presentation is to point out what we have learned and have yet
to learn about the clinical and fundamental aspects of cobalamin (Cbl, vitamin B12)
metabolism from the study ofcongenital defects ofCbl transport. In the original ar-
ticle ofthe same title of 1973 I included the disorders ofintestinal transport [1]. Over
the past decade there have been no important new observations or interpretations of
the congenital defects of Cbl absorption, but there have been many significant
developments in the field of Cbl plasma transport.
The established carriers and functions of the plasma system of man can be sum-
marized briefly. Asthe Cblisreleased from theintestinal carrier, intrinsic factor, it is
bound to the most important plasma carrier, transcobalamin II (TC II). This
specific, trace protein ofplasma can carry about 1.0 ng ofCbl per ml but only about
10 percent ofcirculating TC II is actively carrying Cbl. When Cbl becomes bound to
TC II in vivo the TC II-Cbl is rapidly delivered to specific receptors in many tissues.
The TC II-Cbl is internalized followed by the release of the Cbl to be utilized fur-
ther. Much ofthe evidence of the need for TC II in the recycling of Cbl will be given
subsequently. Only about one-fourth of the circulating Cbl is carried by TC II. The
rest is bound to aglycoprotein known as R binder. R binder is found in granulocytes
and several body fluids including milk, gastric juice, bile, saliva, and tears. The
polypeptide part ofthe molecule is the same for R binder of any source, but the car-
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bohydrate portion, especially the sialic acid, varies greatly. There is no known func-
tion of R binder but in experimental models that R binder of low sialic acid content
will deliver Cbl to receptors for asialoglycoproteins which are restricted to
hepatocytes. These receptors are distinct from those receiving TC II-Cbl; TC II is
not a glycoprotein. The Cbl released from the R binder can then return to the body
pool. As for many body proteins, there are genetic defects of the proteins of the
plasma Cbl transport system, TC II, and R binder. A TC II-Cbl receptor defect has
not been described, but we are currently evaluating a patient in which this is a
possibility. There are congenital defects ofintrinsic factor (IF) and ofthe ileal recep-
tor of IF-Cbl, transport proteins of the gut, the compartment that precedes the cir-
culation. There are also genetic defects of the Cbl metabolism ofcells, the targets of
plasma transport.
Genetic polymorphism has been described for both transcobalamin II (TC II) and
the R type binder ofCbl [2-4]. Determination ofTC II by a single locus with four or
five functionally normal codominant alleles was reported in two simultaneous and
independent investigations [2,3]. Gene frequencies have been determined for dif-
ferent populations [2,5]. Unfortunately a common nomenclature for these elec-
trophoretically distinct alleles has not yet emerged. The congenital deficiency of TC
II, where there is no binding of Cbl to a TC II, is expressed by a "null" allele as
would be expected since the technique of identification of the allele is dependent
upon binding of radioactive Cbl to the TC II [2]. However, a genetically determined
TC II which bound Cbl, but was otherwise nonfunctional, was expressed by a sixth
allele [6]. Similar polymorphism pertains to the determination of R binder, although
only two alleles have been identified [4]. Significantly, the same locus and same
alleles determine the R binder ofseveral body tissues and fluids [4]. This observation
was predicted from the syndrome of congenital deficiency of R binder where R
binder was deficient in all body sources [7].
There have been no new reports ofthe congenital deficiency of R binder, although
there have been additional stucdies ofthe original family [8]. Two fundamentally im-
portant observations were confirmed: (1) The absence of an R binder that would
bind Cbl was universal among five sources expected to contain R binder, and (2)
there were no identifiable clinical consequences ofthe deficiency. In fact, the liver of
a subject homozygous for the defect contained normal amounts ofCbl, and both liver
and serum contained normal proportions of the several forms of Cbl (unpublished
data).
Reports of the congenital deficiency of TC II have in contrast blossomed,
although the syndrome is by no means common. Deficiency of TC II is severely
symptomatic, calling attention to its presence while that of R binder is encountered
only by chance when a person free of evidence of Cbl deficiency is found to have a
low serum Cbl. At this writing, 14 living cases, almost evenly divided between the
sexes and representing 13 families, are known to me. Seven cases have been reported
[9-14], Table 1. The reported cases are thoroughly representative of all cases with
which I have had some contact. Six ofthe reported cases and six ofthe others repre-
sent the most common variant, which is characterized [15] by (1) no measurable
binding of Cbl in vivo or in vitro to TC II, (2) an either much-diminished or absent
immunoreactive TC II. Clinically affected persons are homozygous for the allele ex-
pressed as a nullby current methods [2,6]. Those heterozygous are partially deficient
with one null allele. The second variant may not yet have been observed in the
homozygous state. There is one reported case [13] which seems to be double
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TABLE I
Reported Cases of Congenital Abnormalities of Transcobalamin II
Transcobalamin II
At Onset pg Cbl/ml
Patient Age at Ser. Cbl Ser. folate By RIA Endogenous UBBC
and Ref. Onset Cytopenia* pg/ml ng/ml (Total) (Holo) (Apo)
Variant of nil TC II by RIA and no binding by TC II
An.S. [9] 3.5 wk P 267 20 <50 0 0
Am.S. [9] 5 wk R, PI 855 - <50 0 0
A.B. [10] 3 wk+ P 400 - nil 0 0
-[11] 9 d R, PI 350 - - - 0
N.A. [12] 2 mo R 505 18 - - 0
H.M. [20] 1 mo P - - nil 0 0
V.P. [14] 4-6 wk P N` N` nil 0 0
Variant of some TC II by RIA but no binding by TC II
-[13] 6 wk P - - 352 nil <50
Variant of TC II by RIA and by binding but non functioning TC II
C.B. [16] 12 yr P Age 34 - 6,400 4,384 2,139
>4,000
*P = Pan, R = Red Cells, P1 = Platelets
+After removal from protective environment
++ = Reported only as being normal
Radioimmunoassay (RIA) for TC II by laboratory of [13] for An.S. and Am.S. For A.B., H.M.,
V.P., and C.B. in laboratory of present author as well as holo TC II for An.S., Am.S., A.B., H.M.,
V.P., and C.B.
heterozygous for the classical allele expressed as no Cbl binding and nil im-
munoreactivity with an allele expressed as no binding, but an immunologically
recognized TC II.
Because both variants express a non-functioning TC II, the subject is clinically TC
II deficient. One of the unreported symptomatic cases also has an immunologically
recognizable TC II, but the genetic pattern has not been fully worked out. The third
variant, one living patient, is expressed as being probably homozygous for an allele
conveying a TC II that binds Cbl in vivo and in vitro, reacts with anti human TC II
but does not function [16]. Therefore, the subject is affected clinically but the bind-
ing of Cbl permits an analysis of the genetic pattern which seems to be a sixth allele
[6]. Heterozygotes for all variants have been identified in both published and un-
published families, but, with one exception, have been asymptomatic. One per-
son heterozygous for the null allele became megaloblastic at times of high alcohol
intake [6].
The alleles expressing an abnormal TC II are distributed worldwide. The more
common null allele has been detected in published cases whose national origin was
American [9], Moroccan [10], British [11], Pakistani [12], and Spanish [14]. Un-
published cases have been observed in British (two), Japanese, and Australian
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families. The published case of the immunoreactive, but non-binding TC II was an
American [13] and a similar unpublished case is from Malta. The binding but non-
functioning TC II was observed in a Black American [16].
The combination of clinical expression of these congenital disorders of TC II and
associated observations from the laboratory has revealed much about the function
of this carrier of Cbl. Moreover, the unresolved questions have been put in sharper
focus. The affected infant is born healthy and there is evidence, given below, that
total body Cbl is adequate. The age of clinical onset was within the first six weeks of
life in nine of 14 infants with the no binding type deficiency. In two more reported
cases it was six to nine weeks[12,13]. In one well-observed case, not yet reported, it
was three months, and in another, 16 months. This timing and abruptness of onset
contrast with the later, slower clinical onset, usually in the second year, of Cbl defi-
ciency owing to congenital defects of absorption [1]. The comparison reveals an im-
portant aspect of the function of TCII. It is essential for movement of Cbl from one
tissue to another, although not necessarily from every tissue to every other tissue.
Our earliest studies of TC II in vivo pointed to a function postabsorption, which
happened to be the easiest phase to examine by techniques then available. Subse-
quently it was shown that TC II carried Cbl during recycling [17], as observations in
the congenital deficiency of TC II confirm. The affected infant does not absorb Cbl,
nor for a few months does he need to, yet some tissues appear to be severely depleted
while others contain adequate amounts. The child with congenital malabsorption
but adequate TC II on the other hand can postpone symptoms by freely moving his
declining body Cbl, thus maintaining essential functions.
The nature of the symptoms is also revealing. Megaloblastosis has been universal
and generally severe. Ulcerations of the buccal mucosa and combinations of
vomiting and diarrhea were reported in all seven infants where a complete descrip-
tion is available. Thus, the Cbl deficiency of TC II affects cells of rapid Cbl turn-
over, permitting two possible interpretations. (1) TC II is an essential carrier for
certain classes of cells only. (2) Other cell types also depend on TC II for efficient
Cbl intake, but they are not as dependent on recurrent intake at short intervals as are
rapidly dividing cells. The absence of certain manifestations may be equally signifi-
cant; these will be discussed later.
The prevalence of infection in TC II deficiency has opened up a new field of study
of Cbl metabolism. Each of eight cases for whom enough pertinent information has
been recorded suffered infections, often multiple. Infection was the mode of death
of two older untreated siblings of one child [10]. This child had, shortly after birth,
an impaired ability to make immunoglobulins [18], an incapacity which was restored
by treatment with large amounts of Cbl. Later a killing defect of his granulocytes
was observed [19]. Cbl is needed for cell division, but some additional function is in-
volved here because the impaired Ig response was seen in the first child at a time
when there was no obvious abnormality of lymphocytes and in a second [20] during
hematologic remission. The granulocyte killing defect was observed during other-
wise successful therapy which had induced a hematologic remission [19]. It may be
that these yet undefined requirements for Cbl by leukocytes are more sensitive than
needs for Cbl in maintaining the number, size, and appearance of blood cells.
The intracellular biochemical lesion produced by a deficiency of TC II probably
consists of a deficiency of the coenzymes of Cbl, Ado Cbl, and Me Cbl. The mega-
loblastosis, the response to pharmacologic amounts of Cbl, and the abnormalities of
the dU suppression test [12] all support this thesis. It follows that a deficiency of TC
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II leads to impaired activities of the Cbl-dependent methylmalonyl CoA mutase and
the N5 methyltetrahydrofolate:homocysteine methyltransferase of rapidly dividing
cells. Somewhat disquieting, however, is the report that during a planned relapse of
a TC II deficient child, the leukocytes oxidized propionate normally [21]. Another
common consequence of impaired activity of the mutase is excretion of large
amounts of methylmalonic acid (MMA) but excretion has been low in TC II defi-
ciency. Urinary MMA was normal in two cases [10,21]. In another, MMA was nor-
mal at age one year during relapse, but was slightly increased during a planned
relapse at age 17 years [11]. There was a distinct increase in a fourth case [12]. The
more common forms of Cbl deficiency are also characterized by an increased
urinary excretion of certain sulfur-containing amino acids. These precursors ac-
cumulate from the impaired activity of the Me Cbl dependent methyltransferase in
any depletion of tissue Cbl and in the Cbl C and Cbl D mutants of Cbl metabolism,
inherited disorders where the supply of Cbl is adequate, but synthesis of Me Cbl
and Ado Cbl is impaired [22]. The excretion of homocystine and cystathionine is in-
creased in Cbl deficiency caused by congenital defects of absorption [23] and in
dietary deficiency of Cbl in infancy [24]. The cellular lesion of the deficiency of
TC II should be the same with similar consequences but the excretion of the sulfur-
containing amino acids is not increased [21], Table 2. Probably in the deficiency of
TC II there is thepotential for the same biochemical defects of many types of body
cells as in other forms of Cbl deficiency or where activities of Cbl-dependent en-
zymes are impaired. In TC II deficiency, however, the expression is at first confined
to rapidly dividing cells which contribute only a relatively small fraction ofthe total
Cbl-dependent enzyme activities of the body. If the affected infant could survive
without treatment the insult to his bone marrow and gut, he would then, as more
tissues become depleted of Cbl, excrete increased amounts of MMA, homocystine,
etc.
An alternate possibility is that not all tissues and/or Cbl processes are TC II
dependent. Hepatocytes will take up Cbl bound to R type binder of relatively low
sialic acid content via asialoglycoprotein receptors [26,27]. The Cbl is freed from the
carrier and much returns to the circulation to be bound to TC II while some is ex-
creted into the bile still bound to R binder [26]. Some is converted to coenzyme
forms and incorporated into Cbl-dependent holo enzymes of the liver. Whether this
occurs directly from the free Cbl released from the R binder, as presumably is possi-
ble, or whether it must first be bound to TC II is unknown. Should R Cbl make Cbl
available to the liver in the absence of TC II, there may be enough body activity of
TABLE 2
Urinary Excretion of Products of Faulty Cbl Metabolism in mmol per mol creatinine
Mixed*
Homocysteine Disulfide Cystathionine MMA
Cbl C Mutant'
S.B. [25] 111-147 27-48 37-57 6,920
Nutritional Deficiency
Age 6 mo [24] 96 52 175 8,980
Congenital Deficiency
TC II [21] Trace - 8 <1 mg/ml
*Of homocysteine and cysteine
'One typical case illustrated here. For variation among cases, see Table 1 of [25], Part II
489Cbl-dependent enzymes to control, at least in part, the urinary excretion of MMA,
etc. In the absence of any TC II, however, the Cbl would not be available to tissues
other than the liver and could not prevent malfunction of Cbl-dependent processes
in these tissues. The granulocytes ofTC II deficient children do contain much apo R
binder (unpublished data) which could carry free Cbl to the liver. Nothing is known
about the release and fate of such binder in vivo or of its capacity to pick up free
Cbl. We have examined the sera ofeight TC II deficient persons and while there was
holo R binder in the circulation, there was no binding capacity for added Cbl.
Whereas R binder may effectively carry Cbl into hepatic cells, it is not the only
source of hepatic Cbl. In the congenital deficiency of R binder there were normal
amounts ofAdo and Me Cbl in liver (unpublished data) and excretion of MMA was
not increased [7,8]. Linnell et al. have suggested a defect in the synthesis ofAdo Cbl
but not of Me Cbl by the fibroblasts of TC II deficiency [28], although the observa-
tions of Berliner and Rosenberg [29] on total conversion of free Cbl by TC II defi-
cient fibroblasts did not support this concept. The comparable depressions, and
subsequent increases with treatment, of Me Cbl and Ado Cbl in granulocytes [19]
and erythrocytes [30] are also contradictory.
Neither is the clinical expression of TC II deficiency as broad as that of other
types of Cbl deficiency. Symptoms referable to the central and peripheral nervous
systems are conspicuously absent. One reported patient [11] and two unreported
have been at least mildly mentally retarded, but all were diagnosed rather late and
had been given folic acid without concomitant Cbl. Mental retardation is not
characteristic of simple Cbl deficiency, even of the types originating in early
childhood, although there is one report to the contrary [31]. Again the differential
rate of Cbl turnover may be the key. The cells of the nervous system may retain Cbl
longer than those of the bone marrow and Cbl-deficient infants die or are treated
before the cells of the nervous system become depleted. It is also possible that these
cells are not TC II dependent. In spite of extensive knowledge about Cbl-dependent
enzyme reactions of mammalian tissues, the precise defects responsible for either
megaloblastosis or nervous system malfunction remain unknown. Regrettably, the
experience with the deficiency of TC II has not helped resolve this mystery.
Why is not the megaloblastosis ofCbl deficiency or, for that matter, the effects on
the nervous system, well developed in utero? Infants deficient in TC II are not
anemic until a few weeks after birth. Even infants born of Cbl-deficient mothers do
well for a time [24]. The four well-described infants with the Cbl C mutant [25,32],
three of whom later were megaloblastic, required time to become anemic, although
there was hypersegmentation ofneutrophils at birth in one [25]. Where the mother is
deficient in Cbl, the infant may get just enough to develop in utero. When the fetus
does not have its own TC II, components ofthe maternal transport system may suf-
fice. However, if the cells of the fetus lack the capacity to synthesize Me Cbl or Ado
Cbl [22], how do the Cbl-dependent enzymes function? Perhaps Ado Cbl and Me
Cbl from the mother combine with the respective fetal apo enzymes. Could, how-
ever, the infants' need for Cbl suddenly change at birth? The Cbl content of fetal
tissues of such importance and mass as liver, kidney, heart, and brain is less than
that of the adult counterparts, although there are no transitional data for late fetal
life and infancy [33].
The absorption of Cbl as measured by one or more techniques was abnormal in
the four reported [9-12] and two unreported cases where absorption was deter-
mined. (It was said to be normal in one partially reported case [28], but no details
were given.) The impairment is not a consequence ofCbl deficiency ofthe intestinal
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mucosa because it has persisted during remission. TC II probably combines with the
Cbl coming from the lumen of the intestine within the ileal cell [34]. Thus, the ab-
sence of TC II may interrupt the normal sequence necessary for full absorption. Ab-
sorption of Cbl was, however, normal in the one person with a TC II capable of
binding Cbl and reacting with anti TC II, but non-functioning in the known func-
tion of TC II, promotion of cell uptake of Cbl. The combination of these observa-
tions suggests that it is the Cbl binding function of TC II and not the interaction
with TC II-Cbl cell receptors that is needed for the sequence of absorption.
The congenital defects teach much about the significance of the serum Cbl. Dis-
tinctly low levels usually mean body depletion ofCbl, but in the congenital deficien-
cy of R binders the serum Cbl is pathologically low in spite of normal amonts of
tissue Cbl [7,8]. Low levels should be predictable because about three-fourths of the
serum Cbl is normally bound to R binder [17] and when none is available, the serum
Cbl should be, and is, about a fourth normal [8]. Serum Cbl levels are known for ten
patients with the congenital deficiency of TC II either pre-treatment or at a planned
relapse. In each instance, levels always were normal or high, never low. This pattern
is also predictable. Probably the total body Cbl is normal or nearly so, but the
distribution is faulty. The fraction of serum Cbl bound to TC II should be, and is
[15], absent when there is no fully functioning TC II, but this fraction is, at most,
about one-fourth of the total serum Cbl [17], too small to drop the serum Cbl into a
subnormal range. It is interesting that the serum Cbl is normal in the congenital de-
fects of both Cbl-dependent enzyme activities [25,32]. Here there is no impairment
of absorption or transport ofCbl but in the synthesis ofAdo Cbl and Me Cbl. In the
one case of a TC II that bound Cbl but was otherwise non-functional, the serum Cbl
was much increased (Table 1). Total, apo, and holo TC II were all increased. Prob-
ably the abundant TC II attracted Cbl to the serum while the impaired attachment to
TC II-Cbl receptors permitted it to remain in the circulation.
Experiences with these congenital defects suggest that Cbl leaves the tissues in a
free form and is distributed between the plasma carriers in proportion to the
numbers of open binding sites. The pattern is further modified by rates of removal
which differ between TC II-Cbl and R-Cbl. Of course, if body Cbl is depleted there
is less available to be bound to the carriers and serum Cbl falls. The opposing con-
cept, that the serum Cbl represents an active excretion of already bound Cbl gets no
support from the above and there is further contrary evidence. Ifthe R-Cbl of serum
under usual circumstances represented holo enzymes which contained Cbl being re-
leased from tissues, one or more forms of Cbl would be missing in the deficiency of
R binder. The forms of Cbl in the serum of a subject, W.B., with a congenital defi-
ciency of R binders [8] were measured by thin-layer chromatography and
bioautography. There was binding ofboth Ado Cbl and Me Cbl to the TC II present
(Table 3). Both Me Cbl and Ado Cbl were also observed in the serum of a child defi-
cient in TC II [28].
The response to treatment of those congenitally deficient in TC II has been in-
structive. While the administration of folic acid is not recommended, some affected
children did receive it with improvement in the hematologic manifestations. This
response supports the concept that in Cbl deficiency the ultimate disturbance which
is responsible for the megaloblastic process relates to folate metabolism in some
unknown way. More positive information comes from the response to phar-
macologic amounts of Cbl. Free Cbl is generated in the circulation [15] and free Cbl
when present in adequate amounts will enter human cells to be converted to coen-
zyme forms [15]. This latter point was well documented in a series of definitive
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TABLE 3
Forms of Cbl in the Serum of Congenital Deficiency of R Binder
Values as pg/ml - ( ) = % distribution
Ado Cbl Me Cbl OH Cbl CN Cbl
W.B.-No R Binding 16 12 0 0
(57) (43)
Simultaneous
Control 148 458 101 70
(19) (59) (13) (9)
studies which included fibroblasts from a child deficient in TC II [29]. Thus, the
function of TC II seems to be an enhancement of Cbl uptake by cells, enabling the
small amounts of Cbl that are available in nature to satisfy needs.
An attempt to devise an orderly nomenclature for the disorder of plasma
transport is given in Table 4. For the proteins we prefer the terms transcobalamin II
(TC II, TC 2) and R-binder of Cbl (R CBL). The names for the respective genes
follow logically and once a standard nomenclature is agreed upon forthe alleles con-
veying a normal TC TI [2,31 or R [4], these can be added. The same nomenclature
would be difficult to apply to all but one ofthe abnormal TC II variants because the
method used to study normal alleles is not applicable. Instead, we suggest using
three letters of the place of first description. Our suggestion conforms to recent
guidelines for gene nomenclature [35] and can be added to or altered readily.
Diagnostic suggestions are also implicit in Table 4. Confusion often comes from
what at first glance seems to be an incompatability between levels of serum Cbl and
clinical expression. It is in the deficiency of R binder that the serum Cbl is low, but
the tissues are replete and the person is asymptomatic in respect to Cbl metabolism.
Detection may be at any age and usually comes from an independent reason for
measuring serum Cbl. In the deficiency of TC II there is life-threatening
megaloblastic pancytopenia, infection, mouth ulcers, and gastrointestinal symp-
toms, but the serum Cbl is normal. If the disorder is not treated early in infancy
there is no second chance. Measurement of the capacity of TC II or R to bind Cbl
added in vitro is the most widely available approach to the diagnosis [36,37]. Serum
must be collected before injection of large amounts of Cbl because if binding sites
are thus blocked, the protein will not be detected even when present in normal
amounts. Saliva is a good source for the search for R binder because there are nor-
mally large amounts and contaminating TC II is very low. Thus, the UBBC is essen-
tially a measure of apo R. Specialized techniques such as measure of immunoreac-
tivity, holo R and TC II, and the functions of TC II are best left to laboratories
when they are used frequently.
CONCLUSIONS
The observations from the study of congenital disorders of plasma Cbl transport
support to different degrees several concepts of transport and metabolism of Cbl.
1. R binder of Cbl is nonessential.
2. The R binder ofseveral body tissues and fluids is determined by a singlegenetic
locus with at least two codominant alleles.
3. Transcobalamins II (TC II)
a. is essential under natural circumstances of Cbl intake, but
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TABLE 4
Parameters of Serum Cbl and Proposed Nomenclature
For Congenital Disorders of Plasma Cbl Transport
Carrier Protein as Detected by
Serum Cbl
Genotype Phenotype pg/ml Cbl Binding Immunoreactivity
Congenital Deficiency of R Binder [7,8]
RCBL*BNX/ RCBL BNX Low Nil Reduced
RCBL*BNX
RCB*BNX/ RCBL N N SI. Red.
RCBL
Variant of TC II Deficiency with no detectable TC II [9-12,14]
TC2*SEA/ TC2 SEA N Nil Nil
TC 2*SEA
TC2*SEA/ TC2 N Reduced Reduced
TC2
Variant of Immunoreactive TC II, but No Binding [13]
TC2*DEN/ TC2 DEN-SEA N Nil Reduced
TC 2*SEA
TC2*DEN/ TC2 N Reduced N
TC2
Variant of Increased, Nonfunctioning TC II [16]
TC2*CZA/ TC2 CZA Increased Increased Increased
TC2*CZA
BNX = Bronx, SEA = Seattle, DEN = Denver, CZA = Cardeza
The table gives only combinations already studied. Presumably homozygous TC II Denver would be
expressed by symptoms, normal serum Cbl, normal immunoreacting TC II, but no binding of Cbl to
TC II.
b. can be circumvented by the administration of very large amounts of free
Cbl.
c. TC II promotes entry of small amounts of Cbl into cells, but
d. does not seem to be needed for Cbl metabolism after internalization.
e. TC II is necessary for complete Cbl absorption, and
f. takes part in the recycling of Cbl as well as in the distribution postabsorp-
tion.
g. possibly all tissues do not depend on TC II to the same degree, but more
likely
h. the needs of rapidly dividing cells are more immediate and current while
other cells can go longer without recent TC II-Cbl uptake.
i. TC II is determined by a single genetic locus with several codominant
alleles, some of which are expressed as abnormal forms of TC II.
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